Therapy Area

Autoimmunity disease (AID) is an immune pathological state in which the body's autoimmune tolerance mechanism is dysregulated or destroyed, resulting in the injury of self tissues and organs or abnormal function. Autoimmunity diseases are divided into organ specific autoimmunity diseases and non organ specific autoimmunity diseases.

Organ specific autoimmunity diseases refer to autoimmunity diseases in which patients' lesions are usually limited to specific organs with certain autoantigens, and rarely involve other tissues and organs, such as multiple sclerosis, chronic ulcerative colitis, myasthenia gravis, etc.

Non organ specific autoimmunity diseases refer to the pathological immune reactions of multiple tissues and organs, such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's disease, etc., caused by the lesions of the body against a variety of self antigens.

With the in-depth elucidation of the pathological mechanism of autoimmunity diseases and the discovery of new drug targets, the application of new biological agents in autoimmunity diseases has developed rapidly. Biological agents exert therapeutic effects by blocking inflammatory cytokines or cell surface molecules, such as targeting IL-1, IL-6, TNF-α And monoclonal antibody of IL-17.

Tumor is a new organism formed by abnormal proliferation of cells due to the loss of control of local cells' growth at the gene level under the action of various tumorigenic factors. According to the biological characteristics of tumors and their different degrees of harm to the body, they can be divided into benign and malignant tumors. In China, malignant tumor is one of the main causes of death of patients, and its incidence and mortality are rising, becoming a very serious public health problem.

Tumor therapy has always been a hot area of drug research and development, in which biological drugs play an important role. The biological targeted therapy of tumor is to design the corresponding therapeutic drugs (antibodies, CAR-T, etc.) at the cellular and molecular level, aiming at the identified targets, so as to play the role of inhibiting and killing tumor.

Compared with monotherapy or traditional combination therapy, the dual target properties of bispecific antibodies have key advantages in improving the antitumor efficacy: (1) simultaneously blocking two different targets or mediators that play a major role in the pathogenesis of the disease; (2) Induction of cellular signaling pathways (e.g., proliferation or inflammatory pathways); (3) Retargeting to regulate ADCC; (4) Avoiding the progression of drug resistance and improving the anti proliferative effect; (5) The patient's own cytotoxic T cells are temporarily combined with targeted cancer cells, thereby activating cytotoxic T cells to cause tumor lysis.

Neurological diseases are the general name of various diseases of the central and peripheral nervous system, including epilepsy, cerebrovascular disease, headache (such as migraine), neurodegenerative diseases (such as Parkinson's disease and Alzheimer's disease), neuroimmune / infectious diseases (such as cerebral malaria, meningitis and multiple sclerosis), neurodevelopmental disorders (such as autism spectrum disorders, intellectual development disorders), and traumatic brain and spinal cord injuries.

Neurological diseases are the leading cause of disability and the second leading cause of death worldwide. Worldwide, the burden of neurological diseases measured by the absolute number of disability adjusted life years (DALYs) is increasing, and the corresponding demand for prevention, treatment, and support services is also increasing sharply. Neurological diseases are increasingly concerned by the world.